137 related articles for article (PubMed ID: 16740342)
1. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice.
Morgan D
Neurochem Int; 2006 Jul; 49(2):190-4. PubMed ID: 16740342
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
Vasilevko V; Cribbs DH
Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
Schenk D
Nat Rev Neurosci; 2002 Oct; 3(10):824-8. PubMed ID: 12360327
[No Abstract] [Full Text] [Related]
5. Viral-induced inflammation is accompanied by beta-amyloid plaque reduction in brains of amyloid precursor protein transgenic Tg2576 mice.
Stahl T; Reimers C; Johne R; Schliebs R; Seeger J
Eur J Neurosci; 2006 Oct; 24(7):1923-34. PubMed ID: 17067295
[TBL] [Abstract][Full Text] [Related]
6. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
7. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis.
Lee EB; Leng LZ; Lee VM; Trojanowski JQ
FEBS Lett; 2005 May; 579(12):2564-8. PubMed ID: 15862291
[TBL] [Abstract][Full Text] [Related]
8. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
Philipson O; Hammarström P; Nilsson KP; Portelius E; Olofsson T; Ingelsson M; Hyman BT; Blennow K; Lannfelt L; Kalimo H; Nilsson LN
Neurobiol Aging; 2009 Sep; 30(9):1393-405. PubMed ID: 18192084
[TBL] [Abstract][Full Text] [Related]
9. Nonviral DNA vaccination augments microglial phagocytosis of beta-amyloid deposits as a major clearance pathway in an Alzheimer disease mouse model.
Okura Y; Kohyama K; Park IK; Matsumoto Y
J Neuropathol Exp Neurol; 2008 Nov; 67(11):1063-71. PubMed ID: 18957895
[TBL] [Abstract][Full Text] [Related]
10. Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease.
Malm TM; Magga J; Kuh GF; Vatanen T; Koistinaho M; Koistinaho J
Glia; 2008 Dec; 56(16):1767-79. PubMed ID: 18649403
[TBL] [Abstract][Full Text] [Related]
11. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease.
Morgan D; Gitter BD
Neurobiol Aging; 2004; 25(5):605-8. PubMed ID: 15172737
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-beta immunotherapies in mice and men.
Brendza RP; Holtzman DM
Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
[TBL] [Abstract][Full Text] [Related]
13. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice.
Oksman M; Iivonen H; Hogyes E; Amtul Z; Penke B; Leenders I; Broersen L; Lütjohann D; Hartmann T; Tanila H
Neurobiol Dis; 2006 Sep; 23(3):563-72. PubMed ID: 16765602
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Alzheimer's disease.
McGeer PL; McGeer E
Sci Aging Knowledge Environ; 2004 Jul; 2004(27):pe29. PubMed ID: 15243154
[TBL] [Abstract][Full Text] [Related]
15. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
[TBL] [Abstract][Full Text] [Related]
16. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.
Pihlaja R; Koistinaho J; Malm T; Sikkilä H; Vainio S; Koistinaho M
Glia; 2008 Jan; 56(2):154-63. PubMed ID: 18004725
[TBL] [Abstract][Full Text] [Related]
17. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
[TBL] [Abstract][Full Text] [Related]
18. Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice.
Sohn JH; So JO; Kim H; Nam EJ; Ha HJ; Kim YH; Mook-Jung I
Biochem Biophys Res Commun; 2007 Sep; 361(3):800-4. PubMed ID: 17678618
[TBL] [Abstract][Full Text] [Related]
19. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition.
Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS
Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619
[TBL] [Abstract][Full Text] [Related]
20. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain.
Tamura Y; Hamajima K; Matsui K; Yanoma S; Narita M; Tajima N; Xin KQ; Klinman D; Okuda K
Neurobiol Dis; 2005 Nov; 20(2):541-9. PubMed ID: 15908227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
